GlassScriptPhysician profile
Jimmy V Wolfe
NPI 1093791220
$17,257.82
in general payments reported to CMS, 2019-2025
62 companies · $2,683 in 2025
The $2,683 reported for 2025 was more than what 77% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,908 · 2020: $664 · 2021: $2,313 · 2022: $3,132 · 2023: $2,775 · 2024: $2,784 · 2025: $2,683.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,224 · Education: $16.72.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,224.46 |
| Education | $16.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,521.39 | 2021-2025 | Botox, Qulipta, Ubrelvy |
| Livanova USA, INC. | $1,292.06 | 2019 | |
| Sk Life Science, INC. | $953.95 | 2020-2025 | Xcopri |
| Teva Pharmaceuticals USA, INC. | $840.75 | 2019-2025 | Austedo Xr, Austedo, Ajovy |
| Pfizer INC. | $789.72 | 2022-2025 | |
| Mdd US Operations, LLC | $776.88 | 2022-2025 | Gocovri, Apokyn, Apokyn |
| Lundbeck LLC | $750.21 | 2022-2025 | Vyepti, Rexulti |
| Acadia Pharmaceuticals INC | $638.57 | 2020-2025 | Nuplazid |
| Genzyme Corporation | $613.17 | 2019-2023 | |
| Ucb, INC. | $607.27 | 2019-2025 | Briviact, Nayzilam |
| Alexion Pharmaceuticals, INC. | $501.63 | 2021-2025 | Ultomiris |
| Amgen INC. | $445.03 | 2019-2025 | Uplizna |
| Acorda Therapeutics, INC | $434.09 | 2019-2024 | Inbrija |
| Neurocrine Biosciences, INC. | $431.79 | 2020-2025 | Ingrezza, Ongentys |
| Lilly USA, LLC | $404.05 | 2019-2025 | Emgality, Kisunla, Reyvow |
Show all 62 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $394.98 | 2019-2025 | Leqembi, Skyclarys |
| Avanir Pharmaceuticals, INC. | $381.62 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $378.56 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $355.48 | 2020-2021 | |
| Argenx US, INC. | $349.46 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Impel Pharmaceuticals INC. | $337.44 | 2022-2023 | Trudhesa |
| Otsuka America Pharmaceutical, INC. | $324.42 | 2023-2025 | Nuedexta, Rexulti |
| Eisai INC. | $259.74 | 2019-2025 | |
| Merz Pharmaceuticals, LLC | $249.37 | 2023-2025 | Xeomin, Inbrija, Ampyra |
| Allergan, INC. | $226.47 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $224.95 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $213.25 | 2019-2023 | |
| Genentech USA, INC. | $212.04 | 2019-2022 | |
| Amneal Pharmaceuticals LLC | $195.31 | 2022-2025 | Rytary, Ongentys, Crexont |
| Csl Behring | $189.90 | 2019-2025 | Hizentra |
| Emd Serono, INC. | $182.90 | 2019-2022 | |
| Supernus Pharmaceuticals, INC. | $176.76 | 2019 | |
| Sumitomo Pharma America, INC. | $139.65 | 2023-2024 | Aptiom |
| Takeda Pharmaceuticals U.S.A., INC. | $135.08 | 2021-2022 | |
| Catalyst Pharmaceuticals, INC. | $132.36 | 2022-2024 | Firdapse |
| Mallinckrodt Hospital Products INC. | $103.25 | 2021-2022 | |
| Neurelis, INC. | $103.21 | 2023-2025 | Valtoco |
| Upsher-Smith Laboratories LLC | $100.67 | 2021-2023 | |
| Corium, LLC | $83.28 | 2022-2023 | Adlarity |
| Amylyx Pharmaceuticals, INC. | $75.00 | 2023 | Relyvrio |
| Horizon Therapeutics Plc | $64.85 | 2021-2023 | Uplizna |
| Greenwich Biosciences, INC. | $55.12 | 2019-2020 | |
| Celgene Corporation | $49.78 | 2021-2022 | |
| Jazz Pharmaceuticals INC. | $49.25 | 2019-2022 | |
| Assertio Therapeutics, INC. | $43.89 | 2019-2020 | |
| Abbott Laboratories | $38.56 | 2021-2025 | Eterna |
| Janssen Pharmaceuticals, INC | $37.97 | 2021-2022 | |
| Philips North America LLC | $36.81 | 2020 | |
| Sanofi-Aventis U.S. LLC | $34.42 | 2020 | |
| Ipsen Biopharmaceuticals, INC | $33.50 | 2023 | Dysport |
| Mylan Specialty L.P. | $32.88 | 2023 | Glatiramer Acetate |
| Ge Healthcare | $32.80 | 2022 | |
| Convatec INC. | $29.99 | 2025 | |
| Kyowa Kirin, INC. | $27.80 | 2024 | Nourianz |
| Si-Bone, INC. | $24.48 | 2023 | |
| Xeris Pharmaceuticals, INC. | $21.71 | 2024 | Keveyis |
| Axsome Therapeutics, INC. | $20.17 | 2025 | Symbravo |
| Boston Scientific Corporation | $20.09 | 2025 | Wavewriter Alpha Prime 16 |
| Medtronic, INC. | $19.88 | 2022 | |
| Adamas Pharmaceuticals, INC. | $19.81 | 2019 | |
| Ani Pharmaceuticals, INC. | $19.68 | 2024 | Purified Cortrophin Gel |
| Janssen Biotech, INC. | $18.67 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jimmy Wolfe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.